252 related articles for article (PubMed ID: 38035547)
1. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
Blackmon AL; Hourigan CS
Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
[TBL] [Abstract][Full Text] [Related]
2. Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia.
Wong ZC; Dillon LW; Hourigan CS
Best Pract Res Clin Haematol; 2023 Jun; 36(2):101468. PubMed ID: 37353292
[TBL] [Abstract][Full Text] [Related]
3. SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukemia.
Tedjaseputra A; Russell N; Dillon R
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38734498
[TBL] [Abstract][Full Text] [Related]
4. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
[TBL] [Abstract][Full Text] [Related]
5. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
6. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
7. Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia-Real-World Context.
Patkar N; Kakirde C; Bhanshe P; Joshi S; Chaudhary S; Badrinath Y; Ghoghale S; Deshpande N; Kadechkar S; Chatterjee G; Kannan S; Shetty D; Gokarn A; Punatkar S; Bonda A; Nayak L; Jain H; Bagal B; Menon H; Sengar M; Khizer SH; Khattry N; Tembhare P; Gujral S; Subramanian P
Front Oncol; 2019; 9():450. PubMed ID: 31263671
[No Abstract] [Full Text] [Related]
8. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
9. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
10. Methods of Detection of Measurable Residual Disease in AML.
Zhou Y; Wood BL
Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
[TBL] [Abstract][Full Text] [Related]
11. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of
Grob T; Sanders MA; Vonk CM; Kavelaars FG; Rijken M; Hanekamp DW; Gradowska PL; Cloos J; Fløisand Y; van Marwijk Kooy M; Manz MG; Ossenkoppele GJ; Tick LW; Havelange V; Löwenberg B; Jongen-Lavrencic M; Valk PJM
J Clin Oncol; 2023 Feb; 41(4):756-765. PubMed ID: 36315929
[TBL] [Abstract][Full Text] [Related]
13. Measurable Residual Disease Monitoring by Locked Nucleic Acid Quantitative Real-Time PCR Assay for
Kao HW; Kuo MC; Huang YJ; Chang H; Hu SF; Huang CF; Hung YS; Lin TL; Ou CW; Lien MY; Wu JH; Chen CC; Shih LY
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551690
[TBL] [Abstract][Full Text] [Related]
14. Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
Tiong IS; Loo S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902217
[TBL] [Abstract][Full Text] [Related]
15. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
16. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
Kövy P; Őrfi Z; Bors A; Kozma A; Gopcsa L; Dolgos J; Lovas N; Harasztdombi J; Lakatos V; Király Á; Mikala G; Vályi-Nagy I; Reményi P; Andrikovics H
PLoS One; 2021; 16(6):e0253386. PubMed ID: 34153064
[TBL] [Abstract][Full Text] [Related]
17. MRD evaluation of AML in clinical practice: are we there yet?
Freeman SD; Hourigan CS
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):557-569. PubMed ID: 31808906
[TBL] [Abstract][Full Text] [Related]
18. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F; Chen W
Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
[TBL] [Abstract][Full Text] [Related]
19. MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
Pessach I; Spyropoulos T; Lamprianidou E; Kotsianidis I
Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077826
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia.
Ding Y; Liu Z; Wang H; Xiong S; Zhai Z
Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
